Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone pharmacokinetics and toxicity in paediatric autoimmune and autoinflammatory diseases
NL-OMON51250Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of prednisolone in autoimmune disease, autoinflammatory disease (AID) and inflammatory bowel disease (IBD), sponsored by University Medical Center Utrecht. Primary endpoint: Association between prednisolone exposure and toxicity. Started Mar 2022; status: recruiting.
02
Drugs
prednisolone
03
Conditions
autoimmune diseaseautoinflammatory disease (AID)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON51250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51250.